What is Promimic?
Promimic is at the forefront of developing cutting-edge nanotechnology solutions for implant surfaces. Their proprietary HAnano Surface® technology is designed to significantly improve osseointegration, leading to faster bone growth and enhanced implant stability. This bioactive surface modification has been rigorously validated through extensive research, with over 30 studies and more than 150,000 clinical applications demonstrating its efficacy. The company's primary focus is on serving the medical and dental implant industries, offering advanced technologies that promise superior patient outcomes. Promimic actively collaborates with surgical and dental organizations to integrate its innovative implant solutions into clinical practice.
How much funding has Promimic raised?
Promimic has raised a total of $13.2M across 2 funding rounds:
Unspecified
$10M
Private Equity
$3.2M
Unspecified (2011): $10M with participation from Almi Foretags
Private Equity (2016): $3.2M led by Chalmers Ventures
Key Investors in Promimic
Almi Foretags
Almi Foretags is a Swedish state-owned entity that provides crucial financing and business development support, including loans and venture capital, to small and medium-sized enterprises. Their focus on fostering sustainable growth and preparing businesses for the future makes them a strategic partner for companies seeking long-term stability and expansion.
Chalmers Ventures
Chalmers Ventures is a prominent Nordic tech investor and venture builder, specializing in deep tech innovations. They are instrumental in bringing laboratory research to market, offering a blend of venture creation and investment opportunities to nurture high-potential companies within the entrepreneurial ecosystem.
What's next for Promimic?
With the recent major strategic investment and a substantial total funding amount of $13.2M, Promimic is well-positioned for its next phase of expansion. The company's focus on validated, high-impact nanotechnology for implant surfaces suggests a trajectory towards scaling its operations and broadening its market reach. Future developments will likely involve further clinical validation, strategic partnerships to expand distribution channels, and potentially the development of new applications for its HAnano Surface® technology. The enterprise-level backing indicates confidence in Promimic's business model and its potential to disrupt the implant market with its advanced osseointegration solutions.
See full Promimic company page
